William L. McGuire Memorial Symposium. 1,25(OH)2D3 modulation of mammary tumor cell growth in vitro and in vivo - PubMed (original) (raw)

William L. McGuire Memorial Symposium. 1,25(OH)2D3 modulation of mammary tumor cell growth in vitro and in vivo

S Saez et al. Breast Cancer Res Treat. 1993.

Abstract

The biological role of 1,25(OH)2D3 in controlling Ca++ homeostasis in the body has been identified and widely investigated for a long time. More recently its effect in regulating cell proliferation or differentiated activity was described in a variety of normal and malignant cells. The present study was carried out to investigate the different aspects and biological mechanisms of this activity and to determine if the use of 1,25(OH)2D3 in the treatment of breast cancer patients could be considered. It is found that 1,25(OH)2D3 reduces the proliferation of MCF-7 and BT-20 cells lines regardless of their sex steroid receptor status. This effect is related to the concentration, from 10(-12) M to 10(-8) M. Its amplitude is less in other cell lines, but it opposes the EGF-induced increase of proliferation. It is observed that the proliferation rate of MCF-7 and BT-20 cells is increased when these tumor cells are cocultured with fibroblasts derived from breast tumor biopsies and that 1,25(OH)2D3 reverses this process. Moreover, experiments on DMBA induced mammary tumors in Sprague Dawley rats found that 1,25(OH)2D3 given at non toxic doses reduces significantly the tumor proliferation. These data showed that 1,25(OH)2D3 at low doses is effective on the proliferation of BT-20 and MCF-7 cells and on the paracrine growth stimulatory effect observed in the presence of fibroblasts. They suggest that 1,25(OH)2D3 or related synthetic molecules which are less active on Ca++ metabolism could be useful in the treatment of breast cancer patients.

PubMed Disclaimer

Similar articles

• Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.
  Mehta RG, Moriarty RM, Mehta RR, Penmasta R, Lazzaro G, Constantinou A, Guo L. Mehta RG, et al. J Natl Cancer Inst. 1997 Feb 5;89(3):212-8. doi: 10.1093/jnci/89.3.212. J Natl Cancer Inst. 1997. PMID: 9017001
• Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro.
  Colston KW, Chander SK, Mackay AG, Coombes RC. Colston KW, et al. Biochem Pharmacol. 1992 Aug 18;44(4):693-702. doi: 10.1016/0006-2952(92)90405-8. Biochem Pharmacol. 1992. PMID: 1324683
• Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells.
  Love-Schimenti CD, Gibson DF, Ratnam AV, Bikle DD. Love-Schimenti CD, et al. Cancer Res. 1996 Jun 15;56(12):2789-94. Cancer Res. 1996. PMID: 8665515
• Vitamin D and breast cancer.
  Christakos S. Christakos S. Adv Exp Med Biol. 1994;364:115-8. doi: 10.1007/978-1-4615-2510-3_12. Adv Exp Med Biol. 1994. PMID: 7725955 Review.
• William L. McGuire Memorial Symposium. Control of breast cancer cell growth by steroids and growth factors: interactions and mechanisms.
  Freiss G, Prébois C, Vignon F. Freiss G, et al. Breast Cancer Res Treat. 1993;27(1-2):57-68. doi: 10.1007/BF00683193. Breast Cancer Res Treat. 1993. PMID: 8260730 Review.

Cited by

• Association between plasma 25-hydroxyvitamin D and breast cancer risk.
  Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, Shane E, Terry MB, Desai M, Teitelbaum SL, Neugut AI, Santella RM. Crew KD, et al. Cancer Prev Res (Phila). 2009 Jun;2(6):598-604. doi: 10.1158/1940-6207.CAPR-08-0138. Epub 2009 May 26. Cancer Prev Res (Phila). 2009. PMID: 19470790 Free PMC article.
• Redox regulation of cAMP levels by ascorbate in 1,25-dihydroxy- vitamin D3-induced differentiation of HL-60 cells.
  López-Lluch G, Burón MI, Alcaín FJ, Quesada JM, Navas P. López-Lluch G, et al. Biochem J. 1998 Apr 1;331 ( Pt 1)(Pt 1):21-7. doi: 10.1042/bj3310021. Biochem J. 1998. PMID: 9512457 Free PMC article.
• Prevalence of vitamin D deficiency in patients attending an outpatient cancer care clinic in Boston.
  Tangpricha V, Colon NA, Kaul H, Wang SL, Decastro S, Blanchard RA, Chen TC, Holick MF. Tangpricha V, et al. Endocr Pract. 2004 May-Jun;10(3):292-3. doi: 10.4158/EP.10.3.292. Endocr Pract. 2004. PMID: 15310552 Free PMC article. No abstract available.
• Vitamin D receptors in breast cancer cells.
  Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ, Evans SR. Buras RR, et al. Breast Cancer Res Treat. 1994;31(2-3):191-202. doi: 10.1007/BF00666153. Breast Cancer Res Treat. 1994. PMID: 7881099
• Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan.
  Kawase T, Matsuo K, Suzuki T, Hirose K, Hosono S, Watanabe M, Inagaki M, Iwata H, Tanaka H, Tajima K. Kawase T, et al. Cancer Sci. 2010 May;101(5):1234-40. doi: 10.1111/j.1349-7006.2010.01496.x. Epub 2010 Jan 12. Cancer Sci. 2010. PMID: 20151981 Free PMC article.

References

1. 1. Cell. 1990 May 4;61(3):497-504 - PubMed
2. 1. J Steroid Biochem. 1986 Jan;24(1):373-6 - PubMed
3. 1. Biochem Biophys Res Commun. 1991 Apr 15;176(1):1-6 - PubMed
4. 1. Int J Cancer. 1987 Aug 15;40(2):189-91 - PubMed
5. 1. Science. 1988 May 13;240(4854):889-95 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information